 - AWARE-1 clinical data validate clinical development strategy by confirming pelareoreps anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareoreps synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021 - Strong financial foundation with over 50 million in cash on hand and cash runway to Q4-2022 SAN DIEGO and CALGARY, AB, May 7, 2021 PRNewswire -- Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC today announced its financial results and development highlights for the quarter ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. 